Turning Point Brands, Inc. was informed by the Food and Drug Administration (FDA) that the agency had rescinded its September 14 Marketing Denial Order (MDO) for certain of its vapor products with pending Premarket Tobacco Product Applications (PMTAs) under review. All of TPBs proprietary vapor products, including its Solace branded e-liquids, will continue to be marketed while they remain under review. In its rescission letter to TPB, the FDA stated, Upon further review of the administrative record, FDA found relevant information that was not adequately assessed. Specifically, your applications did contain randomized controlled trials comparing tobacco-flavored ENDS to flavored ENDS as well as several cross-sectional surveys evaluating patterns of use, likelihood of use, and perceptions in current smokers, current ENDS users, former tobacco users, and never users, which require further review. The letter further clarified that at present, in light of the unusual circumstances, FDA has no intention of initiating an enforcement action against the products. In response to the September 14 MDO, the Company had filed a petition for relief and motion to stay the decision in the 6th Circuit Court of Appeals. On October 8, as a result of the rescission letter, TPB withdrew both the petition and motion.